We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

In an effort to better serve our users, we have streamlined our content offering. As a result, we no longer publish new content or update existing content in our Benign Hematology. Visit the 'Content & Subscriptions' tab of your Settings page at any time to update your Dashboard or Newsletter Subscription preferences to continue to see news and information that interests you most.


Journal Scan / Research · November 22, 2022

Intermediate- vs Low-Dose LMWH in Pregnant and Postpartum Women With a History of VTE

The Lancet


Additional Info

Disclosure statements are available on the authors' profiles:

The Lancet
Intermediate-dose versus low-dose low-molecular-weight heparin in pregnant and post-partum women with a history of venous thromboembolism (Highlow study): an open-label, multicentre, randomised, controlled trial
Lancet 2022 Oct 28;[EPub Ahead of Print], IM Bistervels, A Buchmüller, HMG Wiegers, F Ní Áinle, B Tardy, J Donnelly, P Verhamme, AF Jacobsen, AT Hansen, MA Rodger, MT DeSancho, RG Shmakov, N van Es, MH Prins, C Chauleur, S Middeldorp

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading